A recent study has found that a molecule produced naturally by the body may help protect vision from damage caused by high blood sugar, potentially paving the way for new strategies to prevent diabetic retinopathy.
According to the study published in the journal Biomedicine & Pharmacotherapy, this condition affects more than 22% of diabetic patients worldwide, and occurs when high blood sugar causes inflammation and damage to the retinal nerve cells and blood vessels, which may lead to permanent vision loss.
The study was conducted by an international team from the Federal University of São Paulo in Brazil, the State University of São Paulo in Brazil, and the University of Colorado Anschutz in the United States. The researchers tested the peptide Ac2-26, a fragment of an anti-inflammatory protein called Annexin A1, on retinal cells and three-dimensional retinal-like models developed from human stem cells.
The results showed that the peptide:
Reduce inflammation.
Reduce oxidative stress.
- Maintain the energy-producing function of mitochondria.
- Prevents the death of nerve cells exposed to high glucose levels.
Researcher Cristiane Gil, from the Federal University of Sao Paulo, said the results show a protective effect on the retina and offer an indication of a new strategy for disease prevention.
As diabetic retinopathy progresses, inflammation and oxidative stress create a toxic environment that leads to the death of nerve cells in the retina. As the damage worsens, the body attempts to compensate by irregularly forming new blood vessels, but these vessels are fragile and prone to rupture, causing bleeding and further vision loss.
Lead researcher Rafael André da Silva explained that the peptide inhibits pathways that trigger cell death, a mechanism not provided by current treatments, which typically target a late stage of the disease after neurological damage has occurred.
Natalia Vergara, director of the Laboratory of Ocular Development and Translational Technologies at the University of Colorado Anschutz, said that the most important aspect of the study was not just describing the effect of the peptide, but identifying a biological pathway capable of halting deterioration and protecting nerve cells, which could help in developing future treatments.
She added that the collaboration between the two teams was crucial, as the Brazilian researchers have extensive experience studying Annexin A1 and Ac2-26, while the American lab focuses on human retinal cells and microorganisms. These microorganisms allowed researchers to reproduce some of the cellular complexity and stratified organization of the human retina in the lab. Through them, the researchers discovered that the peptide binds to a receptor called FPR2, inhibiting p38 and NOX4 molecules responsible for producing free radicals.
The study also identified a pivotal role for Müller cells, which extend across the retina and play a role in nourishing and protecting it, but when subjected to stress, they can enter a state of overreaction, increasing inflammation and accelerating the death of nerve cells. Ac2-26 helped to suppress this reaction.
The researchers said the discovery opens the door to developing topical treatments that could be used in the very early stages of diabetic retinopathy, before the damage becomes irreversible.
Gill concluded by saying that the study presented, for the first time, a molecule capable of stopping this self-destruction of cells in human tissues, which may pave the way for broader experiments on animals and humans in the next phase.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media


